Epidemiology, Antifungal Therapy, and Outcomes of Invasive Candidiasis Across Six Mexican Tertiary Care Hospitals (2021-2024)

Clicks: 2
ID: 338582
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #323 of 326 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 326 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Invasive candidiasis (IC) is a leading cause of nosocomial mortality; multicenter Latin American data are scarce. We characterized IC epidemiology, management, and outcomes at six Mexican tertiary hospitals and applied a Bayesian hierarchical Weighted-Incidence Syndromic Combination Antibiogram (WISCA) to estimate per-center empiric coverage. Methods Retrospective cohort of 574 consecutive IC episodes (January 2021 – December 2024) across four Mexican states. Thirty-day all-cause mortality was the primary outcome. Mixed-effects logistic regression with hospital random intercept identified predictors; propensity-based and adjusted temporal-trend analyses tested robustness. A Bayesian hierarchical WISCA estimated empiric-regimen coverage. Results Non-albicans species accounted for 64.5% of isolates (N. glabratus 22.8%, C. tropicalis 18.8%, C. parapsilosis 17.2%); Candidozyma auris was not detected. Thirty-day mortality was 36.6% (candidemia 39.5%, similar to a contemporary European cohort); the crude decline from 43.9% in 2021 to 27.4% in 2024 attenuated after adjustment (aOR/year 0.86; 95% CI 0.69–1.09). Septic shock (aOR 8.35) and mechanical ventilation (aOR 2.03) independently predicted mortality; empiric antifungal therapy was associated with lower mortality odds (aOR 0.45). WISCA fluconazole coverage was 78.8% overall (95% HDI 75.5–81.7), below the 80% operational threshold at three of four analytic centers; micafungin exceeded 97% at every center (overall 98.3%, 95% HDI 97.0–99.3). Conclusions Thirty-day IC mortality remains substantial; its crude decline was not independent of case mix and center. Empiric antifungal therapy was associated with lower mortality. In vitro coverage was below threshold for fluconazole at most centers and uniformly high for micafungin, without establishing clinical effectiveness. Non-culture diagnostics remain a priority gap.
Reference Key
openalex_W7225239193 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Luis Asdrúval Zepeda-Gutiérrez, Jaime Briseño-Ramírez, Mauricio Alfredo Ambriz-Alarcón, Edson Alberto Rea-Márquez, Enrique Cervantes‐Pérez, Patricia Cornejo‐Juárez, Ariadna Barajas-Silva, María Fernanda González-Lara, Ever A. Corral-Herrera, Areli Martínez‐Gamboa, Adrián Camacho-Ortíz, Jimena Flores-Garza, Luis Oliverio Ambriz-García, Sharon Michelle Conejo-Angeles, José Raúl Padilla-Gutiérrez, Erick Alejandro Nevárez-Reza, Pedro Martínez-Ayala
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag723
URL
https://doi.org/10.1093/ofid/ofag723
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.